All
  • All
  • Insight
  • Research Services
  • Preclinical CRO
  • Animal Resource Bank
CN
中文 English
Latest News

Latest News

Focusing on cutting-edge technologies and research advancements,
sharing Aniphe BioLab’s achievements in scientific innovation, Professional insights
and practical experience in the fields of laboratory animals and preclinical research.

2026 CKM Guidelines Released: Chronic Diseases Enter the Era of Integrated Cardiorenal-Metabolic Management—It’s Time to Rethink Animal Models

　　Which department should this patient be seen in?

　　A 65-year-old patient presents to the outpatient clinic: BMI 32, fasting plasma glucose 8.9 mmol/L, blood pressure 158/96 mmHg, elevated urine albumin-to-creatinine ratio (UACR), and carotid ultrasound showing plaques. Which specialty should he be referred to?

　　The endocrinology department manages blood glucose, the nephrology department handles proteinuria, the cardiology department oversees blood pressure and atherosclerotic plaques, and the obesity clinic focuses on weight management. Over the past few decades, we have become accustomed to dissecting a single patient into several seemingly unrelated disease modules, with each specialty taking charge of one segment. Yet in reality, disease progression never conforms to departmental boundaries. In this patient, obesity, insulin resistance, hypertension, renal impairment, and cardiovascular risk are, at their core, distinct links in the same pathological cascade—driving one another and amplifying each other’s effects.

　　On June 9, 2026, the four major medical societies—the American Heart Association (AHA), the American College of Cardiology (ACC), the American Diabetes Association (ADA), and the American Society of Nephrology (ASN)—jointly released the first Clinical Practice Guideline on the Cardiovascular–Renal–Metabolic (CKM) Syndrome, formally incorporating this “integrated” perspective into the guideline.

　　

 

　　For those engaged in drug development, this is not merely another English acronym; it is a clear signal:

　　The rules of the game in chronic disease R&D have changed.

　　Preclinical models should also adopt a new approach.

　　WHAT IS CKM?

　　What on earth is CKM talking about?

　　CKM (Cardiovascular–Kidney–Metabolic Syndrome) integrates three categories of health issues into a single framework:

　　Metabolic risk

　　Obesity, abdominal obesity, insulin resistance, prediabetes, type 2 diabetes, dyslipidemia, hypertension

　　Kidney risk

　　Decline in eGFR, increase in UACR, chronic kidney disease (CKD), and its progression

　　Cardiovascular risk

　　ASCVD, heart failure, stroke, peripheral arterial disease, atrial fibrillation

　　It emphasizes not merely grouping several conditions together, but rather the existence of a continuum of risk—characterized by progressive disease progression and mutual amplification—among these three entities. The guideline delineates this continuum using stages 0 through 4: from Stage 0, representing optimal health; to Stage 1, marked by early metabolic risk; Stage 2, when metabolic risk factors or chronic kidney disease (CKD) are present; Stage 3, which encompasses subclinical cardiovascular disease or very high risk (with a 10-year CVD risk ≥20% on the PREVENT equation serving as one of the criteria); and finally, Stage 4, defined as established cardiovascular disease, with Stage 4b specifically referring to cases complicated by renal failure.

　　

 

　　In terms of risk quantification, the guideline emphasizes the use of the PREVENT equation, which for the first time integrates cardiac, renal, and metabolic factors into a single model to estimate 10‑year and 30‑year risks of ASCVD, heart failure, and total cardiovascular disease. According to AHA estimates, nearly 90% of U.S. adults have at least one CKM risk factor. The situation in China is similarly concerning: nationwide large‑scale surveys, such as the China Chronic Disease and Risk Factor Surveillance (CCDRFS), indicate that among Chinese adults aged 18 years and older, the prevalence of CKM syndrome is as high as 83.7%.

　　Nearly 90%

　　At least in the United States, adults have…

　　A CKM risk factor

　　83.7%

　　Adults aged 18 and above in China

　　Prevalence of CKM syndrome

　　This means that nearly 875 million adults nationwide are at various stages of CKM risk. Even more concerning, among the middle-aged and young adult population aged 40 to 59, this proportion has risen to 90.5%. The sheer scale of the affected population is making China the world’s largest and most urgent market for clinical demand for cross-organ metabolic therapies. This represents both an enormous patient pool and a correspondingly massive pharmaceutical market.

　　A Shift in Therapeutic Paradigms: From Single-Disease, Single-Drug Approaches to Cross-Organ Benefits

　　What deserves the closest attention from researchers in the CKM guidelines is their central emphasis on drugs that confer benefits across multiple organs. SGLT2 inhibitors, GLP‑1 receptor agonists, nonsteroidal MRAs (such as finerenone), and RAS inhibitors all share a common feature: each drug exerts multiorgan effects—lowering blood glucose and promoting weight loss while protecting the kidneys and reducing cardiovascular events. The guidelines no longer treat these agents as therapies for a single condition; instead, they view them as tools that simultaneously modulate several key pathways in the CKM. This shift fundamentally alters the questions that a new drug must address.

　　R&D issues are changing.

　　In the past, it was sufficient for an antidiabetic drug to demonstrate glycemic efficacy and cardiovascular safety; today, a competitive CKD‑targeted therapy increasingly needs to show benefits across multiple organs, including metabolism, the kidneys, and the heart.

　　What does this mean for preclinical models?

　　The question then arises: when a drug seeks to demonstrate cross‑organ benefits, can your animal models still keep pace? Traditional preclinical evaluation has been “one‑size‑fits‑one”—a separate model is used for diabetes, another for kidney disease, and yet another for cardiovascular conditions, with each model assessing only the endpoints relevant to its specific organ. This approach worked fine in the era of single‑disease, single‑drug development, but in the age of CKM it runs into three major limitations:

　　1. Cross-organ assessment is challenging: a single glycemic model cannot determine whether a drug confers additional benefits to the kidneys or the heart.

　　2. Analyzing functional progression is challenging: many models are limited to early-stage lesions—for example, in the kidneys they only capture albuminuria and mesangial expansion—yet fail to account for the functional changes that truly drive clinical outcomes, such as a decline in glomerular filtration rate (GFR).

　　3. The evidence chain is incomplete; several unrelated models are used to evaluate each component separately, making it impossible to reconstruct the full picture of a single patient’s sequential progression from “metabolism → kidney → heart.”

　　A single model that simultaneously detects pathologies across multiple organs.

　　Reflects genuine functional progress

　　This is precisely the type of model that is most scarce at present.

　　Written at the end

　　The implementation of the CKM guidelines essentially shifts the R&D paradigm from a disease‑centric approach to one that prioritizes patients’ overall risk profile. For pharmaceutical companies and CROs, this presents both an opportunity—raising the ceiling for cross‑organ‑benefit therapies—and a challenge: evaluating such drugs will require more sophisticated preclinical models.

　　Series Preview | Pain Points → Solutions → Platform

　　02. Why do existing models fail to meet the requirements of CKM?

　　03. What kind of model ensemble can cover the four axes of metabolism, kidney, liver, and heart, and accurately capture the progression of renal function?

　　04. How does Aniphe BioLab build a CKM multi-organ evaluation platform that can be directly integrated?

PREVIOUS:

How should a multi-disease composite mouse model be constructed? Let’s take a look at the CKM approach.

NEXT:

A Guide to Safe Mouse Handling | Manual on Mouse Transport Protocols and Troubleshooting